ZyVersa Therapeutics Announces Peer-Reviewed Publication In Nature Reviews Nephrology Substantiating VAR 200's Rationale For Mediating Transport Of Cholesterol And Lipids Out Of Kidney Cells To Attenuate Progression Of Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics has announced a peer-reviewed publication in Nature Reviews Nephrology that substantiates the rationale for VAR 200's role in mediating the transport of cholesterol and lipids out of kidney cells to attenuate the progression of kidney disease.
October 11, 2023 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ZyVersa Therapeutics' VAR 200 has been substantiated by a peer-reviewed publication for its role in mediating the transport of cholesterol and lipids out of kidney cells, potentially slowing kidney disease progression.
The peer-reviewed publication in a reputable journal like Nature Reviews Nephrology substantiates the potential of ZyVersa's VAR 200 in treating kidney disease. This positive news could increase investor confidence in ZyVersa, potentially leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100